Just had a read of the interview, interesting stuff. Especially the comparisons between medtech and biotech and evidence thresholds etc. Would have been interesting to find out a bit more about how much cashflow the pivotal study requires because of the payment for device debits. Am liking the company, nice to see L1 capital is on the list too, they're onto it.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$4.85 |
Change
-0.150(3.00%) |
Mkt cap ! $75.19M | |||
| Open | High | Low | Value | Volume |
| $5.00 | $5.00 | $4.84 | $15.32K | 3.146K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 882 | $4.84 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.20 | 2136 | 2 |
View Market Depth
| Last trade - 15.14pm 25/07/2025 (20 minute delay) ? |
| AVR (ASX) Chart |